Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : RNAi -- Ignore unavailable to you. Want to Upgrade?

To: Thomas who wrote (299)	11/18/2004 2:29:12 PM
From: tuck	Read Replies (1) \| Respond to of 671

It's a good step, and ALNY bounced back into the $6 range on the news when it was announced a week ago. Message 20754908 How hard they looked for side effects? Dunno. Cheers, Tuck

To: Thomas who wrote (299)	11/22/2004 2:20:49 PM
From: tuck	Read Replies (2) \| Respond to of 671

Interesting post from Yahoo! that claims RNAI -- Sirna Therapeutics, that is -- has already demonstrated in vivo delivery, and in better fashion. Not sure if that is a valid claim, and don't have the time to dig into it. Threadsters are welcome to comment: finance.messages.yahoo.com Edit: sirna.com Slide #12. But not sure how comparable this is. Targets the liver tissue. ALNY's target more ambitious in that it hasn't been druggable by other means to date? Cheers, Tuck

To: Thomas who wrote (299)	11/25/2004 4:29:44 PM
From: Walkingshadow	Read Replies (1) \| Respond to of 671

Hi Thomas, I happen to work in this field. I can tell you that paper in Nature from the European arm of ALNY was a huge advance. It opens the door to many clinical possibilities, and people are all over this. But it is helpful to read the recent commentary in Science... RNA interference is not without problems. Off-target effects seem to be much more common than initially realized, but technical advances to detect and minimize this have developed pretty rapidly also. The guys running ALNY are the best in the world, head and shoulders above the other RNA interference-related companies. Of course, anybody who followed CRA and Craig Venter knows how these things typically work out in the long run---the MBAs always eventually get rid of the PhDs. But still, you can count on ALNY to be a leader in the field. The one I am waiting for is Benitec, a company on the Australian exchange which is supposed to IPO here early next year. (Disclosure: I don't own ALNY) WS